HemaSense Closes Oversubscribed $630K Pre-Seed Round

HemaSense closed an oversubscribed pre-seed financing round in mid-November, raising $630,000 from 19 individual angel investors through a rolling close.

The round reflects strong early support for HemaSense’s mission to improve recovery after catheter-based procedures through earlier detection of bleeding complications. More than 65% of the capital raised came from Arizona-based angel investors, underscoring the strength of the local investor community and its support for emerging medical technology companies in the region.

Together with a $250,000 WearTech grant from the Arizona Commerce Authority, the pre-seed financing supports foundational development activities as HemaSense advances its wearable access site monitoring technology. The funding enables continued progress across product development, clinical preparation, regulatory strategy, and early commercialization planning.

“This is an important inflection point for HemaSense, but it still feels like the beginning of the journey,” said Nathan Friedman, CEO and Co-founder of HemaSense. “Our responsibility is to convert this early capital into meaningful value by building solutions that address real clinical needs. We remain focused on customer needs, rapid decision-making, and capital-efficient execution.”

HemaSense is developing a wearable monitoring system designed to provide early detection and alerts for subcutaneous bleeding events during post-operative recovery. The company is focused on helping care teams identify complications earlier, support faster intervention, and improve recovery for patients following femoral access procedures.